Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan

Clinical Infectious Diseases

Volumn 47, Issue 7, 2008, Pages

  Lai, Chih Cheng ^a   Tan, Che Kim ^c   Huang, Yu Tsung ^b   Chou, Chien Hong ^b   Hung, Chien Ching ^b   Yang, Pan Chyr ^b   Luh, Kwen Tay ^b   Hsueh, Po Ren ^b  

^a Yi Min Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GEMIFLOXACIN; ISEPAMICIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TAIWAN; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TAIWAN;

EID: 52449126201     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591702     Document Type: Article

References (33)

1. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. WHO/HTM/TB/2007.376. Geneva: World Health Organization, 2007.
2. Centers for Disease Control of Taiwan. Statistics of communicable diseases and surveillance report, Republic of China, 2005. Available at: http://www.cdc.gov.tw/public/Data/83241741971.pdf. Accessed 18 March 2008.
3. Lee JJ, Lee CN, Suo J, et al. Drug resistance of Mycobacterium tuberculosis in eastern Taiwan. Tzu Chi Med J 2003; 15:229-33.
4. Chang CE. Trends of primary drug resistance of Mycobacterium tuberculosis isolated from tuberculosis patients in the recent 10 years in Taiwan. In: Taiwan Provincial Health Department. Collected reports of medical research. 1985:137-47.
5. Centers for Disease Control and Prevention. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55:1176.
6. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
7. Hsueh PR, Liu YC, So J, Liu CY, Yang PC, Luh KT. Mycobacterium tuberculosis in Taiwan. J Infect 2006; 52:77-85.
8. Wang JY, Lee LN, Chou CS, et al. Performance assessment of a nested-PCR assay (the RAPID BAP-MTB) and the BD ProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. J Clin Microbiol 2004; 42:4599-603.
9. Wang JY, Lee LN, Hsueh PR, et al. Tuberculous myositis: a rare but existing clinical entity. Rheumatology (Oxford) 2003; 42:836-40.
10. National Committee of Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standards. Wayne, PA: NCCLS, 2003.
11. Lounis N, Ji B, Truffot-Pernot C, Grosset J. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 1997; 41:607-10.
12. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosis tuberculosis. Clin Infect Dis 2003; 37:1448-52.
13. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3:432-42.
14. Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and new antimicrobials. J Clin Microbiol 2006; 44:688-92.
15. Tsao TC, Chiou W, Lin H, et al. Change in demographic picture and increase of drug resistance in pulmonary tuberculosis in a 10-year interval in Taiwan. Infect 2002; 30:75-80.
16. Harrow EM, Rangel JM, Arriega JM, et al. Epidemiology and clinical consequences of drug-resistant tuberculosis in a Guatemalan hospital. Chest 1998; 113:1452-8.
17. Chawla PK, Klapper PJ, Kamholz SL, Pollack AH, Heurich AE. Drug-resistant tuberculosis in an urban population including patients at risk for human immunodeficiency virus infection. Am Rev Respir Dis 1992; 146:280-4.
18. Liaw YS, Hsueh PR, Yu CJ, Wang SK, Yang PR, Luh KT. Drug resistance pattern of Mycobacterium tuberculosis in a university hospital in Taiwan, 1998-2002. J Formos Med Assoc 2004; 103:671-7.
19. Lu PL, Lee YW, Peng CF, et al. The decline of high drug resistance rate of pulmonary Mycobacterium tuberculosis isolates from a southern Taiwan medical centre, 1996-2000. Int J Antimicrob Agents 2003; 21:239-43.
20. Wang PD, Lin RS. Drug-resistant tuberculosis in Taipei, 1996-1999. Am J Infect Control 2001; 29:41-7.
21. Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment. Int J Tuberc Lung Dis 2001; 5:815-23.
22. Al-Tawfiq JA, Al-Muraikhy AA, Abed MS. Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. Chest 2005; 128:3229-32.
23. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368:2142-54.
24. Chiang IH, Yu MC, Bai KJ, et al. Drug resistance patterns of tuberculosis in Taiwan. J Formos Med Assoc 1998; 97:581-3.
25. Wang PD. Epidemiology and control of tuberculosis in Taipei. J Infect 2002; 45:82-7.
26. Yu, MC, Wu HN, Jou R. Extensively drug-resistant tuberculosis, Taiwan. Emerg Infect Dis 2008; 14:849-50.
27. Jeon CY, Hwang SS, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008; 46:42-9.
28. Kim HY, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45:1290-5.
29. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2:265-71.
30. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61:9-18.
31. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1995; 49(Suppl 2):67-75.
32. Tato M, de la Pedrosa EG, Cantón R, et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 2006; 28:75-8.
33. Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5:887-93.